Yes I remember reading that. It's fairly certain that they've completed the first phase of development. The company plans to continue the development process but decided to pursue other delivery systems (cream?) first. My guess is they can only do so much at one time and decided to work on the cream as being the lead off product to market. They're a small company so they can only do so much at one time IMO (I could be wrong about that!). There is no question that they will be using the tablets for their myeloma study in vivo. I don't see another delivery system that is as efficient or effective. In any case I just let it slide, thinking they had to work on their cream in the near term.